REDD1 is a determinant of the sensitivity of renal cell carcinoma cells to autophagy inhibition that can be therapeutically exploited by targeting PIM activity
Cancer Letters · 2025
DOI: 10.1016/j.canlet.2025.217496 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Jennifer S Carew und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology and Oncology, University of Arizona Cancer Center, Tucson, AZ, USA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Autophagy, Proto-Oncogene Proteins c-pim-1, Kidney Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health National Cancer Institute, National Institutes of Health.
Abstract (Originalsprache)
Purpose
Repurposing FDA approved drugs with off-target autophagy inhibition such as chloroquine/hydroxychloroquine (CQ, HCQ) has produced modest anticancer activity in clinical trials, due in part, to a failure to define predictive biomarkers that enable the selection of patients that best respond to this treatment strategy. We identified a new role for REDD1 as a determinant of sensitivity to autophagy inhibition in renal cell carcinoma (RCC). Experimental Design RNA sequencing, qRT-PCR, immunoblotting, gene silencing, knockout and overexpression studies revealed that REDD1 expression is a key regulator of cell death stimulated by autophagy inhibitors. Comprehensive in vitro and in vivo studies were conducted to evaluate the selectivity, tolerability, and efficacy of the PIM kinase inhibitor TP-3654 and CQ in preclinical models of renal cell carcinoma (RCC). Markers of autophagy inhibition and cell death were evaluated in tumor specimens.
Results
Transcriptomic analyses identified REDD1 ( DDIT4 ) as a highly induced gene in RCC cells treated with the PIM kinase inhibitor TP-3654. Focused studies confirmed that PIM1 inhibition was sufficient to induce REDD1 and stimulate autophagy through the AMPK cascade. DDIT4 knockout and overexpression studies established its mechanistic role as a regulator of sensitivity to autophagy inhibition. Inhibition of autophagy with CQ synergistically enhanced the i n vitro and in vivo anticancer activity of TP-3654.
Conclusions
Our findings identify REDD1 as a novel determinant of the sensitivity of RCC cells to autophagy inhibition and support further investigation of PIM kinase inhibition as a precision strategy to drive sensitivity to autophagy-targeted therapies through REDD1 upregulation. Translational Relevance PIM kinases are overexpressed in renal cell carcinoma (RCC) and other malignancies. Here we show that targeting PIM1 significantly upregulates REDD1/ DDIT4 expression, resulting in inhibition of mTOR and autophagy activation. REDD1 induction was determined to be a major factor that regulates the sensitivity of RCC cells to autophagy inhibition. Comprehensive in vitro and in vivo studies in preclinical models of RCC demonstrated that the PIM kinase inhibitor TP-3654 induced REDD1-mediated autophagy and synergistically sensitized cells to autophagy inhibition. Our findings define a new role for REDD1 as a determinant of the sensitivity of RCC cells to autophagy inhibition and demonstrate that antagonizing PIM kinase activity is a precision approach to augment REDD1 levels and potentiate the therapeutic benefit of targeting the autophagy pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Hematology and Oncology, University of Arizona Cancer Center, Tucson, AZ, USA.
- Department of Chemistry and Biochemistry, University of Arizona, Tucson, AZ, USA; Department of Pharmacology and Toxicology, University of Arizona, Tucson, AZ, USA; Arizona Center for Drug Discovery, University of Arizo…
- Department of Urology, University of Arizona, Tucson, AZ, USA.
- Department of Medicine, Division of Hematology and Oncology, University of Arizona Cancer Center, Tucson, AZ, USA; Department of Urology, University of Arizona, Tucson, AZ, USA. Electronic address: snawrocki@arizona.edu.
Förderung
- NCI NIH HHS
- National Institutes of Health National Cancer Institute
- National Institutes of Health
- University of Arizona
- Magyar Tüdőgyógyász Társaság
Zitieren
APA
Carew, J. S., Espitia, C. M., Sureshkumar, S., Carrera Espinoza, M. J., Gamble, M. E., Wang, W., Lee, B. R., & Nawrocki, S. T. (2025). REDD1 is a determinant of the sensitivity of renal cell carcinoma cells to autophagy inhibition that can be therapeutically exploited by targeting PIM activity. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217496
Vancouver
Carew JS, Espitia CM, Sureshkumar S, Carrera Espinoza MJ, Gamble ME, Wang W, et al. REDD1 is a determinant of the sensitivity of renal cell carcinoma cells to autophagy inhibition that can be therapeutically exploited by targeting PIM activity. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217496
BibTeX
@article{Carew2025,
author = {Carew, Jennifer S and Espitia, Claudia M and Sureshkumar, Sruthi and Carrera Espinoza, Maria Janina and Gamble, Madison E and Wang, Wei and Lee, Benjamin R and Nawrocki, Steffan T},
title = {REDD1 is a determinant of the sensitivity of renal cell carcinoma cells to autophagy inhibition that can be therapeutically exploited by targeting PIM activity},
journal = {Cancer Letters},
year = {2025},
doi = {10.1016/j.canlet.2025.217496}
}
EUVIMED